Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New miRNA test could spot hidden virus after transplant

NCT ID NCT07210242

Diagnosis Sponsor: Ting YANG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a new blood test that looks for tiny molecules called miRNAs to detect HCMV infection earlier in people who have received a stem cell transplant. The standard DNA test can miss early signs, so researchers hope this new method will give doctors a head start. About 300 patients in China will participate, and their blood will be checked before and after transplant to compare the two tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PSTM-qPCR miRNA detection technology
What this could lead to
If successful, this could provide a faster, more accurate way to detect HCMV infection after stem cell transplant, allowing earlier treatment and potentially reducing complications.
What could go wrong
This is an observational study, not a treatment trial. The new test may not prove more effective than current DNA testing, and results may not apply outside the study centers in China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include patients scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) at participating transplant centers in China, along with their corresponding stem cell donors. Eligible recipients are patients with hematologic malignancies or related disorders who meet transplant indications. Stem cell sources include peripheral blood stem cells and/or bone marrow plus peripheral blood. All participants must voluntarily join the study and provide written informed consent.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Patients scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Stem cell source includes peripheral blood stem cells and/or bone marrow plus peripheral blood. Ability to understand study procedures and provide written informed consent. Voluntary participation in the study. Exclusion Criteria: * Pregnant or breastfeeding women. Children or individuals with severe cognitive impairment who cannot comply with blood sample collection. Patients with severe comorbidities or other medical conditions judged by the investigator to significantly interfere with study participation or follow-up. Withdrawal of informed consent during the study. Clinical background or history that may introduce significant confounding effects, or when additional sampling frequency is deemed to pose undue risk to the participant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection disease disease arising from reactivation of latent virus graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus infections Graft VS host disease Hematopoietic stem cell transplantation Virus reactivation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.